In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption
Titel:
In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption
Auteur:
Larbouret, Christel Gaborit, Nadège Chardès, Thierry Coelho, Mickaël Campigna, Emmanuelle Bascoul-Mollevi, Caroline Mach, Jean-Pierre Azria, David Robert, Bruno Pèlegrin, André